A new medicine for prostate cancer
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
This research is testing a new medicine called (R)-9b in people with prostate cancer to see if it is safe and how well their bodies tolerate it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11166482 on NIH RePORTER |
What this research studies
Many men with advanced prostate cancer eventually find that their treatments stop working, leading to a condition called Castration Resistant Prostate Cancer (CRPC). Current medicines often become ineffective over time. Our team found a new target in prostate tumors called ACK1, which helps the cancer grow. We developed a new medicine, (R)-9b, designed to block ACK1. This medicine has shown promise in laboratory and animal models by shrinking tumors and boosting the body's immune response against cancer cells. We are now ready to see if this new approach is safe for patients.
Who could benefit from this research
Good fit: Ideal candidates are patients with prostate cancer, particularly those with advanced disease that has become resistant to standard treatments.
Not a fit: Patients whose prostate cancer is still responding well to existing therapies or those without advanced, resistant disease may not be the primary focus for this initial medicine testing.
Why it matters
Potential benefit: If successful, this new medicine could offer a new treatment option for patients with advanced prostate cancer, especially those whose cancer has become resistant to current therapies.
How similar studies have performed: This approach involves a novel inhibitor, (R)-9b, targeting ACK1, which has shown promising results in preclinical models, but this is its first test in humans.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Mahajan, Nupam P — Washington University
- Study coordinator: Mahajan, Nupam P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.